Differentiated Thyroid Cancer
Oncology·MeSH: Neoplasms
Prevalence
5.0 / 100K
6 drugs in development·4 companies·4 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| CABOMETYX | EXELIXIS, INC. (EXEL) |
Phase 3(1)
| Drug | Company |
|---|---|
| dabrafenib | Novartis AG (NVS) |
Phase 2(1)
Unknown(1)
| Drug | Company |
|---|---|
| Cytomel | ENANTA PHARMACEUTICALS INC (ENTA) |
Phase 4(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Differentiated Thyroid Cancer?
BioSniper tracks 6 drugs in development for Differentiated Thyroid Cancer across 4 companies.
How many clinical trials target Differentiated Thyroid Cancer?
There are 4 clinical trials targeting Differentiated Thyroid Cancer tracked by BioSniper.
What is the prevalence of Differentiated Thyroid Cancer?
The estimated prevalence of Differentiated Thyroid Cancer is approximately 5.0 per 100,000 population.
Deep-dive into Differentiated Thyroid Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis